ASM INTERNATIONAL AIMS TO ACHIEVE NET ZERO BY 2035
Almere, The Netherlands
September 28, 2021, 7:45 a.m. CET
ASM International N.V. (Euronext Amsterdam: ASM) announces today its target to achieve Net Zero emissions by 2035.
ASM recognizes the importance of the climate crisis to all stakeholders. Accordingly, this Net Zero aim is a priority in ASM’s sustainability strategy.
“We have built a solid foundation of achievements in sustainability over the past years. We now take important steps forward with our sustainability strategy for the next horizon, of which this Net Zero target is a priority, as we strive to make a positive impact in the world.” said Benjamin Loh, CEO of ASM International.
The target includes setting science based targets for Scope 1, 2, and 3 Greenhouse Gas (GHG) emissions, with the aim: to reduce emissions as near to zero as possible, to maximize the sourcing of electricity from renewable sources, and to neutralize remaining emissions.
As the climate crisis transcends the actions of any one company, industry, or country, we intend to collaborate across our value chain for collective global impact. Further, ASM strives to embody high standards in the definition, scope, transparency, and realization of this target.
ASM’s next steps in its 2035 Net Zero target will be:
- ASM has completed a detailed study of its Scope 2 emissions with the assistance of a recognized external expert, based on which it will source 100% of its electricity from renewable sources for all of its global operations from 2024 onward. Before that time ASM has the aim to:
- Source 100% of its electricity from renewable sources for key sites in the U.S., The Netherlands, Finland, Japan, and Singapore, from 2021 onwards. Relative to its 2020, baseline this would represent a ~70% absolute reduction of ASM Scope 1 and 2 GHG emissions.
- Source 100% of its electricity from renewable sources for the remainder of its global operations from 2024 onwards. Relative to its 2020 baseline, this would represent a ~90% absolute reduction of ASM Scope 1 and 2 GHG emissions.
- We intend to align our target to the Paris Agreement 1.5°C pathway;
- Size ASM’s Scope 3 footprint and set a target for all scopes before the end of 2022;
- Accelerate the further energy and resource efficiency improvement of its products;
- Provide further interim goals on the pathway to Net Zero; and
- Develop an emissions compensation and neutralization strategy to address residual emissions.
About ASM International
ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability,changes in import/export regulations, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Investor and media contact:
T: +31 88 100 8500
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
MINTIE Provides Proven Worldwide COVID Surge Capacity Solution as International Infection Prevention Week Highlights Tireless Efforts and Bravery of Worldwide Infection Control Community19.10.2021 01:00:00 CEST | Press release
AZUSA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- With the worldwide healthcare industry commemorating International Infection Prevention Week, October 17-23, MINTIE LLC, a third-generation healthcare product innovator and an Alliance Environmental Group company, continues its efforts at infection prevention in the fight against COVID-19 and the Delta Variant. The company introduced its first line of Environmental Containment Units (ECUs) in 2003 to control the spread of harmful airborne particles during construction or maintenance activities. Since then, MINTIE has continued to push the innovation process forward and now, its ECU4 mobile environmental containment units are currently being used to support surge requirements for airborne isolation in the continued fight against the transmission of COVID-19. https://youtu.be/O0sS1-LpDvc Since January 2021, over 1,500 ECU4s have been deployed in 400+ Japanese healthcare facilities to provide temporary airborne isolation support as part of
REC Silicon – Settlement of claims under indemnity loans18.10.2021 22:54:59 CEST | Press release
Moses Lake, WA, October 18, 2021: Reference is made to previous announcements from REC Silicon ASA ("REC") of 20 December 2019 and 18 November 2020 about claims from Nordea of NOK 150 million under certain indemnity arrangements. REC and Nordea have now entered into a settlement agreement pursuant to which Nordea releases all claims against REC, against payment of NOK 95,000,000, of which approx. NOK 32 million is settled through an existing escrow account of REC with Nordea, and the balance is to be settled in one payment of approx. NOK 63 million by the end of February 2022. For further information, please contact: James A. May II, Chief Financial Officer Phone: +1 509 989 1023 Email: email@example.com Nils O. Kjerstad, IR Contact Phone: +47 9135 6659 Email: firstname.lastname@example.org About REC Silicon REC Silicon is a leading producer of advanced silicon materials, delivering high-purity polysilicon and silicon gas to the solar and electronics industries worldwide. We combine 30 y
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 202118.10.2021 22:00:00 CEST | Press release
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial resultsThe fifth poster presentation demonstrates that lanifibranor improves NASH, fibrosis and diastolic dysfunction in a hamster model of diet-induced NASH and diastolic dysfunction Daix (France), Long Island City (New York, United States), October 18, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that five scientific abstracts have been selected for poster presentations during the upcoming The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases (AASLD) on November 12-15, 2021. The fir
Bast Fibre Technologies acquires German textile processing facility to fulfil customer demand18.10.2021 18:12:39 CEST | Press release
VICTORIA, British Columbia, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bast Fibre Technologies (BFT), a manufacturer of specialty natural fibres for the global nonwoven industry, announces the acquisition of Faser Veredlung Tönisvorst (FVT), an ISO 9001 certified textile processing facility located in Tönisvorst Germany. This purchase enables BFT to immediately increase capacity to meet customer demand for its sustainable bast fibres and provides a firm platform for expansion and continued growth. With over twenty years of fibre processing experience, FVT is located within close proximity to major European centres for bast crop cultivation and nonwoven fabric construction. This transaction follows BFT’s strategy of establishing low carbon, regional supply chains by sourcing, producing, and selling within specific regions. The facility is currently being expanded with the installation of specialty refining equipment specifically designed to optimize natural bast fibres for use in a variety of no
Lenny Clarhäll ställer ut i Bror Hjorths Hus18.10.2021 17:20:13 CEST | Pressemelding
Uppsala, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Lenny Clarhäll - Profiler 23 okt - 28 nov 2021 Bror Hjorths Hus, Uppsala Utställningen visar främst skulpturer och målningar från de senaste tio åren. Lenny Clarhäll (född 1938) har varit bildkonstnär i sextio år och har en rad viktiga utställningar och betydande offentliga verk bakom sig. Läsandet, inte minst sentida poesi, och musik, har satt djupa spår i hans sökande efter abstraktion i ett sparsmakat bildspråk. Ett antal bilder har rubriken Ljudet av aska och är en direkt följd av detta. Mötet med ryska ikoner har satt avtryck i strikt formmässiga målningar med byggnader och arkitektur som grundläggande motiv i utställningen. De skulpturer som visas har samlingsnamnet Profiler. Detta är berättelser om möten med andra konstnärer som har haft stor betydelse för hans utveckling, översatta i trä och brons. Utställning Profiler pågår 23 oktober-28 november 2021 på Bror Hjorths Hus i Uppsala. Utställningskommissarie är museets chef Tomas Järlide
trivago N.V.'s Third Quarter 2021 Earnings Release Scheduled for November 1, 202118.10.2021 15:30:00 CEST | Press release
DÜSSELDORF, GERMANY – October 18, 2021 - trivago N.V. (NASDAQ: TRVG) announced today that it will release its financial results for the third quarter for the period ended September 30, 2021 on Monday, November 1, 2021. On the same day, trivago N.V.'s management will conduct a webcast beginning at 1:15 PM CET / 8:15 AM EDT. These items will be available in the Investor Relations section of the company's website at https://ir.trivago.com/. A replay of the call is expected to be available for at least three months. About trivago N.V. trivago N.V. (NASDAQ: TRVG) is a global hotel and accommodation search platform. We are focused on reshaping the way travelers search for and compare different types of accommodations, such as hotels, vacation rentals and apartments, while enabling our advertisers to grow their businesses by providing them with access to a broad audience of travelers via our websites and apps. Our platform allows travelers to make informed decisions by personalizing their sea
Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists18.10.2021 14:00:00 CEST | Press release
~ Discovery efforts will focus on small molecules with differentiated clinical profiles to harness the broad potential of orexin agonism across different indications~ ~ First time Schrödinger is applying its computational platform in an orexin agonist setting enabled by Orexia’s structural biology capabilities ~ NEW YORK, BOSTON and LONDON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Schrödinger (Nasdaq: SDGR) and Centessa Pharmaceuticals plc (“Centessa”) (Nasdaq: CNTA), together with subsidiary Orexia Therapeutics (“Orexia”), today announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor (OX2R), which is known to play a role in a broad spectrum of sleep disorders including narcolepsy. The collaboration provides Orexia with substantial access to Schrödinger’s entire computational platform as well as Schrödinger’s extensive expertise in ultra-large-scale deployment of its technology. Orexia will leverage Schrödinger’s computational platfo